𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Endometrial ablation for the treatment of menorrhagia: A comparison of patients with normal, enlarged, and fibroid uteri

✍ Scribed by Jack Lomano


Publisher
John Wiley and Sons
Year
1991
Tongue
English
Weight
460 KB
Volume
11
Category
Article
ISSN
0196-8092

No coin nor oath required. For personal study only.

✦ Synopsis


One hundred sixty-one patients underwent endometrial ablation with the NdYAG laser for the treatment of refractory menorrhagia. Patients were divided into one of three groups: those with a normal-sized uterus; those with an enlarged uterus (> than 10 cm); and those with uterine fibroids, which had been documented clinically, ultrasonographically, or by a combination of hysteroscopy and laparoscopy or by one or the other. All patients were considered candidates for hysterectomy. Both preoperatively and postoperatively, patients monitored their menstrual cycles and evaluated their flow according to predetermined categories of amenorrhea, light flow, normal flow, heavy flow, and severe flow. After treatment, 68% of patients with normal-sized uterus and 91% of patients with an enlarged uterus (> than 10 cm) and 88% of patients with uterine fibroids became amenorrheic or had light flow. None of the patients in this last group have had to undergo hysterectomy. This study indicates that the patient with an enlarged or fibroid uterus may not have contraindications for endometrial ablation. Endometrial ablation may be effective in at least temporarily controlling bleeding in those patients with enlarged or myomatous uterus.


πŸ“œ SIMILAR VOLUMES


A comparison of sumanirole versus placeb
✍ Carlos Singer; Janice Lamb; Amanda Ellis; Gary Layton πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 146 KB πŸ‘ 1 views

## Abstract To assess the safety and efficacy of sumanirole, a highly selective dopamine agonist, versus placebo and demonstrate its noninferiority to ropinirole, 614 patients with early Parkinson's disease (PD) were treated with sumanirole, 1 to16 mg/day; ropinirole, 0.75 to 24 mg/day; or placebo.

Comparison of the efficacy and safety of
✍ Rene-Jean Bensadoun; Jamel Daoud; Brahim El Gueddari; Laurent Bastit; Rene Gourm πŸ“‚ Article πŸ“… 2007 πŸ› John Wiley and Sons 🌐 English βš– 152 KB πŸ‘ 2 views

## Abstract ## BACKGROUND. Topical antifungal treatments are recommended but rarely used as first‐line therapy for oropharyngeal candidiasis (OPC) in patients with cancer. Miconazole Lauriad 50‐mg mucoadhesive buccal tablet (MBT) Loramyc reportedly delivered rapid and prolonged, effective concentr